Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Jul 2016 Planned primary completion date changed from 1 Aug 2019 to 1 Jul 2019.
- 22 Jul 2016 Status changed from not yet recruiting to recruiting.